Discovery of cis - N -(1-(4-(methylamino)cyclohexyl)indolin-6-yl)thiophene- 2-carboximidamide: A 1,6-disubstituted indoline derivative as a highly selective inhibitor of human neuronal nitric oxide synthase (nNOS) without any cardiovascular liabilities

Subhash C. Annedi, Jailall Ramnauth, Shawn P. Maddaford, Paul Renton, Suman Rakhit, Gabriela Mladenova, Peter Dove, Sarah Silverman, John S. Andrews, Milena D. Felice, Frank Porreca

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

A series of 1,6-disubstituted indoline derivatives were synthesized and evaluated as inhibitors of human nitric oxide synthase (NOS) designed to mitigate the cardiovascular liabilities associated with previously reported tetrahydroquinoline-based selective neuronal NOS inhibitors due to higher lipophilicity (J. Med. Chem. 2011, 54, 5562-5575). This new series produced similar potency and selectivity among the NOS isoforms and was devoid of any cardiovascular liabilities associated with QT prolongation due to hERG activity or endothelial NOS mediated vasoconstriction effect. The SAR studies led to the identification of cis-45, which was shown to reverse thermal hyperalgesia in vivo in the spinal nerve ligation model of neuropathic pain with excellent safety profile (off-target activities at 80 CNS related receptors/ion channels/transporters). The results presented in this report make cis-45 as an ideal tool for evaluating the potential role of selective nNOS inhibitors in CNS related disorders where excess NO produced by nNOS is thought to play a crucial role.

Original languageEnglish (US)
Pages (from-to)943-955
Number of pages13
JournalJournal of Medicinal Chemistry
Volume55
Issue number2
DOIs
StatePublished - Jan 26 2012

Fingerprint

Nitric Oxide Synthase Type I
Nitric Oxide Synthase
Spinal Nerves
Nitric Oxide Synthase Type III
Hyperalgesia
Neuralgia
Vasoconstriction
Ion Channels
Ligation
Protein Isoforms
Safety
indoline
N-(1-(4-(methylamino)cyclohexyl)indolin-6-yl)thiophene-2-carboximidamide

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Discovery of cis - N -(1-(4-(methylamino)cyclohexyl)indolin-6-yl)thiophene- 2-carboximidamide : A 1,6-disubstituted indoline derivative as a highly selective inhibitor of human neuronal nitric oxide synthase (nNOS) without any cardiovascular liabilities. / Annedi, Subhash C.; Ramnauth, Jailall; Maddaford, Shawn P.; Renton, Paul; Rakhit, Suman; Mladenova, Gabriela; Dove, Peter; Silverman, Sarah; Andrews, John S.; Felice, Milena D.; Porreca, Frank.

In: Journal of Medicinal Chemistry, Vol. 55, No. 2, 26.01.2012, p. 943-955.

Research output: Contribution to journalArticle

Annedi, Subhash C. ; Ramnauth, Jailall ; Maddaford, Shawn P. ; Renton, Paul ; Rakhit, Suman ; Mladenova, Gabriela ; Dove, Peter ; Silverman, Sarah ; Andrews, John S. ; Felice, Milena D. ; Porreca, Frank. / Discovery of cis - N -(1-(4-(methylamino)cyclohexyl)indolin-6-yl)thiophene- 2-carboximidamide : A 1,6-disubstituted indoline derivative as a highly selective inhibitor of human neuronal nitric oxide synthase (nNOS) without any cardiovascular liabilities. In: Journal of Medicinal Chemistry. 2012 ; Vol. 55, No. 2. pp. 943-955.
@article{88553452c87f439681a8b7a49f4f38cb,
title = "Discovery of cis - N -(1-(4-(methylamino)cyclohexyl)indolin-6-yl)thiophene- 2-carboximidamide: A 1,6-disubstituted indoline derivative as a highly selective inhibitor of human neuronal nitric oxide synthase (nNOS) without any cardiovascular liabilities",
abstract = "A series of 1,6-disubstituted indoline derivatives were synthesized and evaluated as inhibitors of human nitric oxide synthase (NOS) designed to mitigate the cardiovascular liabilities associated with previously reported tetrahydroquinoline-based selective neuronal NOS inhibitors due to higher lipophilicity (J. Med. Chem. 2011, 54, 5562-5575). This new series produced similar potency and selectivity among the NOS isoforms and was devoid of any cardiovascular liabilities associated with QT prolongation due to hERG activity or endothelial NOS mediated vasoconstriction effect. The SAR studies led to the identification of cis-45, which was shown to reverse thermal hyperalgesia in vivo in the spinal nerve ligation model of neuropathic pain with excellent safety profile (off-target activities at 80 CNS related receptors/ion channels/transporters). The results presented in this report make cis-45 as an ideal tool for evaluating the potential role of selective nNOS inhibitors in CNS related disorders where excess NO produced by nNOS is thought to play a crucial role.",
author = "Annedi, {Subhash C.} and Jailall Ramnauth and Maddaford, {Shawn P.} and Paul Renton and Suman Rakhit and Gabriela Mladenova and Peter Dove and Sarah Silverman and Andrews, {John S.} and Felice, {Milena D.} and Frank Porreca",
year = "2012",
month = "1",
day = "26",
doi = "10.1021/jm201564u",
language = "English (US)",
volume = "55",
pages = "943--955",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Discovery of cis - N -(1-(4-(methylamino)cyclohexyl)indolin-6-yl)thiophene- 2-carboximidamide

T2 - A 1,6-disubstituted indoline derivative as a highly selective inhibitor of human neuronal nitric oxide synthase (nNOS) without any cardiovascular liabilities

AU - Annedi, Subhash C.

AU - Ramnauth, Jailall

AU - Maddaford, Shawn P.

AU - Renton, Paul

AU - Rakhit, Suman

AU - Mladenova, Gabriela

AU - Dove, Peter

AU - Silverman, Sarah

AU - Andrews, John S.

AU - Felice, Milena D.

AU - Porreca, Frank

PY - 2012/1/26

Y1 - 2012/1/26

N2 - A series of 1,6-disubstituted indoline derivatives were synthesized and evaluated as inhibitors of human nitric oxide synthase (NOS) designed to mitigate the cardiovascular liabilities associated with previously reported tetrahydroquinoline-based selective neuronal NOS inhibitors due to higher lipophilicity (J. Med. Chem. 2011, 54, 5562-5575). This new series produced similar potency and selectivity among the NOS isoforms and was devoid of any cardiovascular liabilities associated with QT prolongation due to hERG activity or endothelial NOS mediated vasoconstriction effect. The SAR studies led to the identification of cis-45, which was shown to reverse thermal hyperalgesia in vivo in the spinal nerve ligation model of neuropathic pain with excellent safety profile (off-target activities at 80 CNS related receptors/ion channels/transporters). The results presented in this report make cis-45 as an ideal tool for evaluating the potential role of selective nNOS inhibitors in CNS related disorders where excess NO produced by nNOS is thought to play a crucial role.

AB - A series of 1,6-disubstituted indoline derivatives were synthesized and evaluated as inhibitors of human nitric oxide synthase (NOS) designed to mitigate the cardiovascular liabilities associated with previously reported tetrahydroquinoline-based selective neuronal NOS inhibitors due to higher lipophilicity (J. Med. Chem. 2011, 54, 5562-5575). This new series produced similar potency and selectivity among the NOS isoforms and was devoid of any cardiovascular liabilities associated with QT prolongation due to hERG activity or endothelial NOS mediated vasoconstriction effect. The SAR studies led to the identification of cis-45, which was shown to reverse thermal hyperalgesia in vivo in the spinal nerve ligation model of neuropathic pain with excellent safety profile (off-target activities at 80 CNS related receptors/ion channels/transporters). The results presented in this report make cis-45 as an ideal tool for evaluating the potential role of selective nNOS inhibitors in CNS related disorders where excess NO produced by nNOS is thought to play a crucial role.

UR - http://www.scopus.com/inward/record.url?scp=84856380860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856380860&partnerID=8YFLogxK

U2 - 10.1021/jm201564u

DO - 10.1021/jm201564u

M3 - Article

C2 - 22175766

AN - SCOPUS:84856380860

VL - 55

SP - 943

EP - 955

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 2

ER -